Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug?

Michele Fornaro, Fabio Bandini, Luca Cestari, Christian Cordano, Carla Ogliastro, Claudio Albano, Domenico De Berardis, Matteo Martino, Andrea Escelsior, Giulio Rocchi, Pantaleo Fornaro, Concetta De Pasquale

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the central nervous system dopaminergic activity, namely the standard electroretinogram (ERG) technique, suggested a reduction of the dopaminergic activity of the main ERG parameter, the b-wave, by pure melatonin, notably a hormone devoid of any antidepressant activity. Therefore, the antidepressant effects of the melatonergic antidepressant drug agomelatine should be reflected by a differential b-wave trend at ERG versus the effect exerted by pure melatonin, which was eventually found to be due to a contrasting effect on central dopaminergic transmission between the two drugs. Objective and methods: The aim of the present preliminary ERG study carried out on healthy volunteers (n=23) receiving agomelatine was to explore the impact of this antidepressant drug on b-wave amplitude and latency of cones in daylight conditions using standard ERG. Results: As postulated, agomelatine induced an enhancement of retinal dopaminergic activity, in contrast to what has been previously documented for melatonin. Conclusion: Given the limits of this explorative study, especially the lack of a control group and that of a luminance response function to measure retinal sensitivity, further studies in clinical samples are recommended to allow more tenable conclusions about the potential role of ERG in discriminating between 5-HT antagonism and melatonergic (MT) agonism in relationship to the claimed antidepressant effect of agomelatine.

Original languageEnglish
Pages (from-to)907-914
Number of pages8
JournalNeuropsychiatric Disease and Treatment
Volume10
DOIs
Publication statusPublished - May 20 2014
Externally publishedYes

Fingerprint

S 20098
Antidepressive Agents
Melatonin
Central Nervous System
Receptor, Serotonin, 5-HT2C
Proxy
Serotonin
Healthy Volunteers
Hormones
Control Groups

Keywords

  • Dopamine, 5-HT2C
  • Electroretinogram
  • ERG

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Electroretinographic modifications induced by agomelatine : A novel avenue to the understanding of the claimed antidepressant effect of the drug? / Fornaro, Michele; Bandini, Fabio; Cestari, Luca; Cordano, Christian; Ogliastro, Carla; Albano, Claudio; De Berardis, Domenico; Martino, Matteo; Escelsior, Andrea; Rocchi, Giulio; Fornaro, Pantaleo; De Pasquale, Concetta.

In: Neuropsychiatric Disease and Treatment, Vol. 10, 20.05.2014, p. 907-914.

Research output: Contribution to journalArticle

Fornaro, M, Bandini, F, Cestari, L, Cordano, C, Ogliastro, C, Albano, C, De Berardis, D, Martino, M, Escelsior, A, Rocchi, G, Fornaro, P & De Pasquale, C 2014, 'Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug?', Neuropsychiatric Disease and Treatment, vol. 10, pp. 907-914. https://doi.org/10.2147/NDT.S63459
Fornaro, Michele ; Bandini, Fabio ; Cestari, Luca ; Cordano, Christian ; Ogliastro, Carla ; Albano, Claudio ; De Berardis, Domenico ; Martino, Matteo ; Escelsior, Andrea ; Rocchi, Giulio ; Fornaro, Pantaleo ; De Pasquale, Concetta. / Electroretinographic modifications induced by agomelatine : A novel avenue to the understanding of the claimed antidepressant effect of the drug?. In: Neuropsychiatric Disease and Treatment. 2014 ; Vol. 10. pp. 907-914.
@article{1bb059964d7043e093de5f86844cfcf6,
title = "Electroretinographic modifications induced by agomelatine: A novel avenue to the understanding of the claimed antidepressant effect of the drug?",
abstract = "Background: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the central nervous system dopaminergic activity, namely the standard electroretinogram (ERG) technique, suggested a reduction of the dopaminergic activity of the main ERG parameter, the b-wave, by pure melatonin, notably a hormone devoid of any antidepressant activity. Therefore, the antidepressant effects of the melatonergic antidepressant drug agomelatine should be reflected by a differential b-wave trend at ERG versus the effect exerted by pure melatonin, which was eventually found to be due to a contrasting effect on central dopaminergic transmission between the two drugs. Objective and methods: The aim of the present preliminary ERG study carried out on healthy volunteers (n=23) receiving agomelatine was to explore the impact of this antidepressant drug on b-wave amplitude and latency of cones in daylight conditions using standard ERG. Results: As postulated, agomelatine induced an enhancement of retinal dopaminergic activity, in contrast to what has been previously documented for melatonin. Conclusion: Given the limits of this explorative study, especially the lack of a control group and that of a luminance response function to measure retinal sensitivity, further studies in clinical samples are recommended to allow more tenable conclusions about the potential role of ERG in discriminating between 5-HT antagonism and melatonergic (MT) agonism in relationship to the claimed antidepressant effect of agomelatine.",
keywords = "Dopamine, 5-HT2C, Electroretinogram, ERG",
author = "Michele Fornaro and Fabio Bandini and Luca Cestari and Christian Cordano and Carla Ogliastro and Claudio Albano and {De Berardis}, Domenico and Matteo Martino and Andrea Escelsior and Giulio Rocchi and Pantaleo Fornaro and {De Pasquale}, Concetta",
year = "2014",
month = "5",
day = "20",
doi = "10.2147/NDT.S63459",
language = "English",
volume = "10",
pages = "907--914",
journal = "Neuropsychiatric Disease and Treatment",
issn = "1176-6328",
publisher = "Dove Medical Press Ltd.",

}

TY - JOUR

T1 - Electroretinographic modifications induced by agomelatine

T2 - A novel avenue to the understanding of the claimed antidepressant effect of the drug?

AU - Fornaro, Michele

AU - Bandini, Fabio

AU - Cestari, Luca

AU - Cordano, Christian

AU - Ogliastro, Carla

AU - Albano, Claudio

AU - De Berardis, Domenico

AU - Martino, Matteo

AU - Escelsior, Andrea

AU - Rocchi, Giulio

AU - Fornaro, Pantaleo

AU - De Pasquale, Concetta

PY - 2014/5/20

Y1 - 2014/5/20

N2 - Background: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the central nervous system dopaminergic activity, namely the standard electroretinogram (ERG) technique, suggested a reduction of the dopaminergic activity of the main ERG parameter, the b-wave, by pure melatonin, notably a hormone devoid of any antidepressant activity. Therefore, the antidepressant effects of the melatonergic antidepressant drug agomelatine should be reflected by a differential b-wave trend at ERG versus the effect exerted by pure melatonin, which was eventually found to be due to a contrasting effect on central dopaminergic transmission between the two drugs. Objective and methods: The aim of the present preliminary ERG study carried out on healthy volunteers (n=23) receiving agomelatine was to explore the impact of this antidepressant drug on b-wave amplitude and latency of cones in daylight conditions using standard ERG. Results: As postulated, agomelatine induced an enhancement of retinal dopaminergic activity, in contrast to what has been previously documented for melatonin. Conclusion: Given the limits of this explorative study, especially the lack of a control group and that of a luminance response function to measure retinal sensitivity, further studies in clinical samples are recommended to allow more tenable conclusions about the potential role of ERG in discriminating between 5-HT antagonism and melatonergic (MT) agonism in relationship to the claimed antidepressant effect of agomelatine.

AB - Background: Agomelatine, the first melatonergic antidepressant, has been postulated to enhance the dopaminergic activity at the central nervous system by 5-hydroxytryptamine receptor type 2C (5-HT2C) antagonism, yet the impact of melatonergic agonism on this pathway is unclear. Previous studies employing simplified, yet reliable, proxy (retinal) measures of the central nervous system dopaminergic activity, namely the standard electroretinogram (ERG) technique, suggested a reduction of the dopaminergic activity of the main ERG parameter, the b-wave, by pure melatonin, notably a hormone devoid of any antidepressant activity. Therefore, the antidepressant effects of the melatonergic antidepressant drug agomelatine should be reflected by a differential b-wave trend at ERG versus the effect exerted by pure melatonin, which was eventually found to be due to a contrasting effect on central dopaminergic transmission between the two drugs. Objective and methods: The aim of the present preliminary ERG study carried out on healthy volunteers (n=23) receiving agomelatine was to explore the impact of this antidepressant drug on b-wave amplitude and latency of cones in daylight conditions using standard ERG. Results: As postulated, agomelatine induced an enhancement of retinal dopaminergic activity, in contrast to what has been previously documented for melatonin. Conclusion: Given the limits of this explorative study, especially the lack of a control group and that of a luminance response function to measure retinal sensitivity, further studies in clinical samples are recommended to allow more tenable conclusions about the potential role of ERG in discriminating between 5-HT antagonism and melatonergic (MT) agonism in relationship to the claimed antidepressant effect of agomelatine.

KW - Dopamine, 5-HT2C

KW - Electroretinogram

KW - ERG

UR - http://www.scopus.com/inward/record.url?scp=84901468535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901468535&partnerID=8YFLogxK

U2 - 10.2147/NDT.S63459

DO - 10.2147/NDT.S63459

M3 - Article

AN - SCOPUS:84901468535

VL - 10

SP - 907

EP - 914

JO - Neuropsychiatric Disease and Treatment

JF - Neuropsychiatric Disease and Treatment

SN - 1176-6328

ER -